Evidence map›Paper›PMID 27299311›Full record

ReviewPharmaceutical research2016

Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date.

Daniel Bobo, Kye J Robinson, Jiaul Islam, Kristofer J Thurecht, Simon R Corrie

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pharmaceutical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 929 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
929citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

929 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Analyzing Molecular Determinants of Nanodrugs' Cytotoxic Effects.International journal of molecular sciences · 2025
    Pooled it
  2. Trial
  3. Green-synthesized Nanoparticles as Emerging Antidepressant and Anxiolytic Candidates: A Critical Review of Preclinical Evidence and Translational Prospects.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

869 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Daniel BoboCentre for Advanced Imaging, University of Queensland, St Lucia, QLD, 4072, Australia.
Kye J RobinsonARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Queensland node, St Lucia, 4072, QLD, Australia.
Jiaul IslamAustralian Institute for Bioengineering and Nanotechnology, University of Queensland, St Lucia, QLD, 4072, Australia.
Kristofer J ThurechtCentre for Advanced Imaging, University of Queensland, St Lucia, QLD, 4072, Australia.
Simon R CorrieCentre for Advanced Imaging, University of Queensland, St Lucia, QLD, 4072, Australia. simon.corrie@monash.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this review we provide an up to date snapshot of nanomedicines either currently approved by the US FDA, or in the FDA clinical trials process. We define nanomedicines as therapeutic or imaging agents which comprise a nanoparticle in order to control the biodistribution, enhance the efficacy, or otherwise reduce toxicity of a drug or biologic. We identified 51 FDA-approved nanomedicines that met this definition and 77 products in clinical trials, with ~40% of trials listed in clinicaltrials.gov started in 2014 or 2015. While FDA approved materials are heavily weighted to polymeric, liposomal, and nanocrystal formulations, there is a trend towards the development of more complex materials comprising micelles, protein-based NPs, and also the emergence of a variety of inorganic and metallic particles in clinical trials. We then provide an overview of the different material categories represented in our search, highlighting nanomedicines that have either been recently approved, or are already in clinical trials. We conclude with some comments on future perspectives for nanomedicines, which we expect to include more actively-targeted materials, multi-functional materials ("theranostics") and more complicated materials that blur the boundaries of traditional material categories. A key challenge for researchers, industry, and regulators is how to classify new materials and what additional testing (e.g. safety and toxicity) is required before products become available.

Indexed as

Clinical Trials as TopicDrug ApprovalHumansNanomedicineNanoparticlesTissue DistributionUnited Statesclinical trialsFDAnanomedicinenanoparticlesnanopharmaceuticalsnanotherpeutics

Identifiers

PMID27299311

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.